Appointments:
Medical Oncologist & Associate Professor, Division of Medical Oncology
Chair Hepatopancreobiliary (HPB) Oncology Halifax
Director of Research, Division of Medical Oncology
Associate Member, Beatrice Hunter Cancer Research Institute
Affiliations:
Dalhousie University, Nova Scotia Health
Research Interests:
Pancreatic cancer, hepatocellular carcinoma, biliary tract cancers, breast cancer, real world evidence, translational research, clinical trial design
The focus of my research has been primarily pancreatic and hepatobiliary tumors. As a medical oncologist and lead for the HPB Cancer disease site, I am involved in several industry and academic clinical trials as the lead investigator. My focus is on creating a provincial pancreatic cancer database and associated tumor bank. As the lead investigator of The PANcreatic Cancer Research platform to Examine biomarkers And Systemic treatment outcomes (PANCREAS) project, I am working with other investigators to tackle the questions about referral patterns, and patient outcomes in the province and begin to investigate biomarkers for pancreatic cancer.
What brought you to your current institution? My family fell in love with Nova Scotia on our multiple vacations here and when the opportunity presented itself to become a medical oncologist in Halifax, I jumped at the chance.
Hometown: Mississauga, Ontario
Why are you interested in your area of research? As a HPB specialist, I see a large proportion of HPB cancers in the province. With the poor outcomes I see from these deadly diseases, the importance of research is critical to try and improve outcomes. Real world research allows for analysis of barriers to patient care and outcomes. Translational research brings bench work research to patient care, informing clinical trials which are needed to show whether new treatments work for patients.
Learn More about my research: https://medicine.dal.ca/departments/department-sites/medicine/divisions/medical-oncology/our-people/faculty/ravi-ramjeesingh.html
Twitter Account: Follow me on Twitter @medoncdoc
Involvement with BHCRI to date:
I am an associate member of BHCRI since 2018. Two of my trainees have taken part in the BHCRI training program. I have been a member of the BCHRI training committee since 2020. I have also presented at the BHCRI Seminar series.
Phone:
902 473 6106
Contact:
Bethune Building, QEII Health Sciences Centre, 1276 South Park Street, Halifax, Nova Scotia, Canada B3H 2Y9
Publications:
Graham C, Orr C, Bricks CS, Hopman WM, Hammad N, Ramjeesingh R. A retrospective analysis of the role of proton pump inhibitors on colorectal cancer disease survival. Curr Oncol 2016 Dec;23(6):e583-e588.
Wang A, Ramjeesingh R, Chen CH, Hurlbut D, Hammad N, Mulligan LM, Nicol C, Feilotter HE, Davey S. Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma. Curr Oncol 2016 June;23(3):e171-e178.
Ramjeesingh R, Orr C, Bricks CS, Hopman WM, Hammad N. A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival. Curr Oncol 2016 Apr;23(2):e116-122.
Ramjeesingh R, Meyer RM, Brouwers M, Booth CM. Alignment of practice guidelines with targeted therapy drug funding policies in Ontario. Curr Oncol 2013 Feb;20(1):e21-33.